2015
Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence
Verplaetse TL, Weinberger AH, Smith PH, Cosgrove KP, Mineur YS, Picciotto MR, Mazure CM, McKee SA. Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence. Nicotine & Tobacco Research 2015, 17: 486-495. PMID: 25762760, PMCID: PMC4432402, DOI: 10.1093/ntr/ntu280.Peer-Reviewed Original ResearchConceptsSmoking cessationNoradrenergic systemClinical evidenceTobacco dependenceNoradrenergic activityMedication developmentPoor smoking cessation outcomesCause of morbiditySmoking cessation outcomesStress reactivitySex-specific mechanismsLower quit ratesNicotine-related reinforcementCurrent medicationsMedication effectivenessNicotine reinforcementCessation outcomesNoradrenergic agentsQuit ratesTreatment strategiesTobacco useNoradrenergic compoundsSmoking outcomesTreatment developmentWomen
2014
A behavioural smoking treatment based on perceived risks of quitting: A preliminary feasibility and acceptability study with female smokers
Weinberger AH, Pittman B, Mazure CM, McKee SA. A behavioural smoking treatment based on perceived risks of quitting: A preliminary feasibility and acceptability study with female smokers. Addiction Research & Theory 2014, 23: 108-114. PMID: 25904837, PMCID: PMC4402999, DOI: 10.3109/16066359.2014.933813.Peer-Reviewed Original ResearchFemale smokersPoint prevalence smoking abstinenceStage II clinical trialsEnd of treatmentDaily cigarette smokersTreatment development studyNovel behavioral treatmentPrimary outcomeCigarette smokersSmoking abstinenceSmoking interventionsClinical trialsMayo ClinicStandard counselingRisk counselingSmoking treatmentSmoking outcomesSmokersBehavioral treatmentManualized treatmentTreatment developmentAcceptability studyCounseling conditionMonthsGreater reduction